請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9012完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 楊雅倩 | |
| dc.contributor.author | Yen-Chun Lai | en |
| dc.contributor.author | 賴彥君 | zh_TW |
| dc.date.accessioned | 2021-05-20T20:06:33Z | - |
| dc.date.available | 2014-09-15 | |
| dc.date.available | 2021-05-20T20:06:33Z | - |
| dc.date.copyright | 2009-09-15 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-11 | |
| dc.identifier.citation | 1. Gunter, M.J. and M.F. Leitzmann, Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem, 2006. 17(3): p. 145-56.
2. Takahashi, H., K. Yoneda, A. Tomimoto, H. Endo, T. Fujisawa, H. Iida, H. Mawatari, Y. Nozaki, T. Ikeda, T. Akiyama, M. Yoneda, M. Inamori, Y. Abe, S. Saito, A. Nakajima, and H. Nakagama, Life style-related diseases of the digestive system: colorectal cancer as a life style-related disease: from carcinogenesis to medical treatment. J Pharmacol Sci, 2007. 105(2): p. 129-32. 3. Orlando, F.A., D. Tan, J.D. Baltodano, T. Khoury, J.F. Gibbs, V.J. Hassid, B.H. Ahmed, and S.J. Alrawi, Aberrant crypt foci as precursors in colorectal cancer progression. J Surg Oncol, 2008. 98(3): p. 207-13. 4. Compton, C.C. and F.L. Greene, The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin, 2004. 54(6): p. 295-308. 5. Kurnat-Thoma, E.L., Hereditary nonpolyposis colorectal cancer (Lynch syndrome): molecular pathogenesis and clinical approaches to diagnosis and management for nurses. Biol Res Nurs, 2008. 9(3): p. 185-99. 6. Ashley, D.J., A male-female differential in tumour incidence. Br J Cancer, 1969. 23(1): p. 21-5. 7. Knudson, A.G., Jr., Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A, 1971. 68(4): p. 820-3. 8. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell, 1990. 61(5): p. 759-67. 9. Piard, F., C. Chapusot, A. Ecarnot-Laubriet, T. Ponnelle, and L. Martin, Molecular markers of heterogeneity in colorectal cancers and adenomas. Eur J Cancer Prev, 2002. 11(1): p. 85-97. 10. Takayama, T., K. Miyanishi, T. Hayashi, Y. Sato, and Y. Niitsu, Colorectal cancer: genetics of development and metastasis. J Gastroenterol, 2006. 41(3): p. 185-92. 11. Kitisin, K. and L. Mishra, Molecular biology of colorectal cancer: new targets. Semin Oncol, 2006. 33(6 Suppl 11): p. S14-23. 12. Grady, W.M. and S.D. Markowitz, Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet, 2002. 3: p. 101-28. 13. Baker, S.J., E.R. Fearon, J.M. Nigro, S.R. Hamilton, A.C. Preisinger, J.M. Jessup, P. vanTuinen, D.H. Ledbetter, D.F. Barker, Y. Nakamura, R. White, and B. Vogelstein, Chromosome 17 deletions and p53 gene mutations in colorectal 39 carcinomas. Science, 1989. 244(4901): p. 217-21. 14. Alberici, P. and R. Fodde, The role of the APC tumor suppressor in chromosomal instability. Genome Dyn, 2006. 1: p. 149-70. 15. Segditsas, S. and I. Tomlinson, Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene, 2006. 25(57): p. 7531-7. 16. Lynch, J.P. and T.C. Hoops, The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am, 2002. 16(4): p. 775-810. 17. Wong, J.J., N.J. Hawkins, and R.L. Ward, Colorectal cancer: a model for epigenetic tumorigenesis. Gut, 2007. 56(1): p. 140-8. 18. Grady, W.M. and J.M. Carethers, Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology, 2008. 135(4): p. 1079-99. 19. Soreide, K., E.A. Janssen, H. Soiland, H. Korner, and J.P. Baak, Microsatellite instability in colorectal cancer. Br J Surg, 2006. 93(4): p. 395-406. 20. Young, J., M. Jenkins, S. Parry, B. Young, D. Nancarrow, D. English, G. Giles, and J. Jass, Serrated pathway colorectal cancer in the population: genetic consideration. Gut, 2007. 56(10): p. 1453-9. 21. Bossard, C., M.G. Denis, S. Bezieau, K. Bach-Ngohou, A. Bourreille, C.L. Laboisse, and J.F. Mosnier, Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. Oncol Rep, 2007. 18(5): p. 1093-7. 22. Shivapurkar, N., A.K. Virmani, Wistuba, II, S. Milchgrub, B. Mackay, J.D. Minna, and A.F. Gazdar, Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res, 1999. 5(1): p. 17-23. 23. Tanner, M.M., R.A. Karhu, N.N. Nupponen, A. Borg, B. Baldetorp, T. Pejovic, M. Ferno, D. Killander, and J.J. Isola, Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol, 1998. 153(1): p. 191-9. 24. Shivapurkar, N., S. Sood, Wistuba, II, A.K. Virmani, A. Maitra, S. Milchgrub, J.D. Minna, and A.F. Gazdar, Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res, 1999. 59(15): p. 3576-80. 25. Shivapurkar, N., A. Maitra, S. Milchgrub, and A.F. Gazdar, Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol, 2001. 32(2): p. 169-77. 26. Suzuki, S.T., Recent progress in protocadherin research. Exp Cell Res, 2000. 261(1): p. 13-8. 27. Yagi, T. and M. Takeichi, Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev, 2000. 14(10): p. 1169-80. 40 28. Takeichi, M., The cadherin superfamily in neuronal connections and interactions. Nat Rev Neurosci, 2007. 8(1): p. 11-20. 29. Suzuki, S.T., Structural and functional diversity of cadherin superfamily: are new members of cadherin superfamily involved in signal transduction pathway? J Cell Biochem, 1996. 61(4): p. 531-42. 30. Sano, K., H. Tanihara, R.L. Heimark, S. Obata, M. Davidson, T. St John, S. Taketani, and S. Suzuki, Protocadherins: a large family of cadherin-related molecules in central nervous system. Embo J, 1993. 12(6): p. 2249-56. 31. Morishita, H. and T. Yagi, Protocadherin family: diversity, structure, and function. Curr Opin Cell Biol, 2007. 19(5): p. 584-92. 32. Redies, C., K. Vanhalst, and F. Roy, delta Protocadherins: unique structures and functions. Cell Mol Life Sci, 2005. 62(23): p. 2840-52. 33. Hirano, S., Q. Yan, and S.T. Suzuki, Expression of a novel protocadherin, OL-protocadherin, in a subset of functional systems of the developing mouse brain. J Neurosci, 1999. 19(3): p. 995-1005. 34. Uemura, M., S. Nakao, S.T. Suzuki, M. Takeichi, and S. Hirano, OL-Protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat Neurosci, 2007. 10(9): p. 1151-9. 35. Nagase, T., R. Kikuno, K.I. Ishikawa, M. Hirosawa, and O. Ohara, Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro. DNA Res, 2000. 7(1): p. 65-73. 36. Wolverton, T. and M. Lalande, Identification and characterization of three members of a novel subclass of protocadherins. Genomics, 2001. 76(1-3): p. 66-72. 37. Aoki, E., R. Kimura, S.T. Suzuki, and S. Hirano, Distribution of OL-protocadherin protein in correlation with specific neural compartments and local circuits in the postnatal mouse brain. Neuroscience, 2003. 117(3): p. 593-614. 38. Muller, K., S. Hirano, L. Puelles, and C. Redies, OL-protocadherin expression in the visual system of the chicken embryo. J Comp Neurol, 2004. 470(3): p. 240-55. 39. Murakami, T., T. Hijikata, M. Matsukawa, H. Ishikawa, and H. Yorifuji, Zebrafish protocadherin 10 is involved in paraxial mesoderm development and somitogenesis. Dev Dyn, 2006. 235(2): p. 506-14. 40. Nakao, S., A. Platek, S. Hirano, and M. Takeichi, Contact-dependent promotion of cell migration by the OL-protocadherin-Nap1 interaction. J Cell Biol, 2008. 182(2): p. 395-410. 41. Ding, K., Y. Su, L. Pang, Q. Lu, Z. Wang, S. Zhang, S. Zheng, J. Mao, and Y. Zhu, Inhibition of apoptosis by down-regulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells. Carcinogenesis, 2008. 42. Miyamoto, K., T. Fukutomi, S. Akashi-Tanaka, T. Hasegawa, T. Asahara, T. Sugimura, and T. Ushijima, Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer, 2005. 116(3): p. 407-14. 43. Ying, J., H. Li, T.J. Seng, C. Langford, G. Srivastava, S.W. Tsao, T. Putti, P. Murray, A.T. Chan, and Q. Tao, Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene, 2006. 25(7): p. 1070-80. 44. Ying, J., Z. Gao, H. Li, G. Srivastava, P.G. Murray, H.K. Goh, C.Y. Lim, Y. Wang, T. Marafioti, D.Y. Mason, R.F. Ambinder, A.T. Chan, and Q. Tao, Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol, 2007. 136(6): p. 829-32. 45. Yu, J., Y.Y. Cheng, Q. Tao, K.F. Cheung, C.N. Lam, H. Geng, L.W. Tian, Y.P. Wong, J.H. Tong, J.M. Ying, H. Jin, K.F. To, F.K. Chan, and J.J. Sung, Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology, 2009. 136(2): p. 640-51 e1. 46. Perl, A.K., P. Wilgenbus, U. Dahl, H. Semb, and G. Christofori, A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 1998. 392(6672): p. 190-3. 47. Rudini, N., A. Felici, C. Giampietro, M. Lampugnani, M. Corada, K. Swirsding, M. Garre, S. Liebner, M. Letarte, P. ten Dijke, and E. Dejana, VE-cadherin is a critical endothelial regulator of TGF-beta signalling. Embo J, 2008. 27(7): p. 993-1004. 48. Yu, J.S., S. Koujak, S. Nagase, C.M. Li, T. Su, X. Wang, M. Keniry, L. Memeo, A. Rojtman, M. Mansukhani, H. Hibshoosh, B. Tycko, and R. Parsons, PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene, 2008. 27(34): p. 4657-65. 49. Yoshida, K. and S. Sugano, Identification of a novel protocadherin gene (PCDH11) on the human XY homology region in Xq21.3. Genomics, 1999. 62(3): p. 540-3. 50. Imoto, I., H. Izumi, S. Yokoi, H. Hosoda, T. Shibata, F. Hosoda, M. Ohki, S. Hirohashi, and J. Inazawa, Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res, 2006. 66(9): p. 4617-26. 51. Junghans, D., I.G. Haas, and R. Kemler, Mammalian cadherins and protocadherins: about cell death, synapses and processing. Curr Opin Cell Biol, 2005. 17(5): p. 446-52 52. Makarova, O., E. Kamberov, and B. Margolis, Generation of deletion and point mutations with one primer in a single cloning step. Biotechniques, 2000. 29(5): p. 970-2. 53. Nakao, S., M. Uemura, E. Aoki, S.T. Suzuki, M. Takeichi, and S. Hirano, Distribution of OL-protocadherin in axon fibers in the developing chick nervous system. Brain Res Mol Brain Res, 2005. 134(2): p. 294-308. 54. Rouget-Quermalet, V., J. Giustiniani, A. Marie-Cardine, G. Beaud, F. Besnard, D. Loyaux, P. Ferrara, K. Leroy, N. Shimizu, P. Gaulard, A. Bensussan, and C. Schmitt, Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas. Oncogene, 2006. 25(19): p. 2807-11. 55. Terry, S., L. Queires, S. Gil-Diez-de-Medina, M.W. Chen, A. de la Taille, Y. Allory, P.L. Tran, C.C. Abbou, R. Buttyan, and F. Vacherot, Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate, 2006. 66(10): p. 1100-13. 56. Okazaki, N., N. Takahashi, S. Kojima, Y. Masuho, and H. Koga, Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation. Carcinogenesis, 2002. 23(7): p. 1139-48. 57. Chen, M.W., F. Vacherot, A. De La Taille, S. Gil-Diez-De-Medina, R. Shen, R.A. Friedman, M. Burchardt, D.K. Chopin, and R. Buttyan, The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene, 2002. 21(51): p. 7861-71. 58. Yang, X., M.W. Chen, S. Terry, F. Vacherot, D.K. Chopin, D.L. Bemis, J. Kitajewski, M.C. Benson, Y. Guo, and R. Buttyan, A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res, 2005. 65(12): p. 5263-71. 59. Waha, A., S. Guntner, T.H. Huang, P.S. Yan, B. Arslan, T. Pietsch, O.D. Wiestler, and A. Waha, Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia, 2005. 7(3): p. 193-9. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9012 | - |
| dc.description.abstract | 大腸直腸癌高居國人癌症致死率第三位,已知致癌路徑主要有三個:造成基因不穩定的失異合性、微衛星不穩定,以及表觀基因修飾的調控。本實驗室先前分析大腸直腸癌檢體在第四號染色體上微衛星標記的缺失情形,進而發現PCDH10(protocadherin 10) variant 1 mRNA 在大腸腫瘤檢體表現量顯著較正常黏膜組織低,並因受到DNA 高度甲基化而降低基因表現,此初步結果支持PCDH10 可能為大腸直腸癌相關之抑癌基因,因此選擇PCDH10 基因為研究目標,了解PCDH10在大腸直腸癌致癌路徑中是否扮演抑癌基因的角色。PCDH10 有兩種mRNAvariants,本論文經由建構PCDH10 表現載體於大腸直腸癌細胞株HCT116 進行蛋白質表現,以研究此兩種基因產物之可能功能。結果顯示暫時性大量表現PCDH10variant 1 會抑制細胞生長及侵犯能力,而大量表現PCDH10 variant 2 僅影響細胞生長能力。由於無法獲得會表現PCDH10 蛋白的混合穩定株(mixed stable clones),我們利用兩株PCDH10 variant 1 單一穩定株(single stable clones)及一株PCDH10 variant 2 單一穩定株進行功能研究。結果顯示在PCDH10 variant 1 蛋白表現量高時具有抑制細胞生長及群落形成能力,而PCDH10 variant 2 的表現則不影響細胞的這些特性。此外,為確認PCDH10 在細胞中表現位置,建構表現PCDH10 和綠色螢光蛋白融合的載體,也以免疫螢光染色檢PCDH10 兩種蛋白在細胞中的位點。以共軛焦顯微鏡觀察發現PCDH10 variant 1 和variant 2 均表現在細胞膜上,並且兩者有共同存在(co-localization)的現象。由以上結果我們推測PCDH10 於細胞膜上並進行蛋白功能,其中,PCDH10 variant 1 在大腸直腸癌細胞株HCT116 可能具有抑癌基因功能。 | zh_TW |
| dc.description.abstract | Colorectal cancer (CRC) is one of the most common malignancies and is the third leading cause of cancer death in Taiwan. Three major pathways, loss of heterozygosity, microsatellite instability and epigenetic regulation are demonstrated in CRC tumorigenesis. To identify putative tumor suppressor genes associated with CRC, deletion mapping on chromosome 4 was performed by loss of heterozygosity analysis with colorectal cancer paired tissues. Previous data figured out that expression of PCDH10 variant 1 is significantly down-regulated in tumor tissues than their paired normal mucosa. On the other hand, the expression of PCDH10 is regulated by epigenetic modification. These data support that PCDH10 might be a putative tumor suppressor gene associated with in colorectal cancer. It has been reported that PCDH10 gene is transcribed into 2 kinds of mRNA variants. In the present study, PCDH10 mammalian expression vectors were constructed and over-expressed in colorectal cancer cell line, HCT116, and then the cells were analyzed by functional assays. The results showed transient over-expression of PCDH10 variant 1 could suppress cell proliferation and invasion, while over-expression of PCDH10 variant 2 only inhibited cell proliferation. Furthermore, we got two of PCDH10 variant 1 single stable clones and one of PCDH10 variant 2. PCDH10 variant 1 single stable clones could repress cell growth and colony formation in protein expression level-dependent manner. There is no same effect in PCDH10 variant 2 stable expression clone. Moreover, through construction of PCDH10-GFP fusion protein vector and immunofluorecent stain of the
PCDH10 variant 1 single stable clone, we identified the localization of PCDH10 protein in cells. Both PCDH10 variant 1 and variant 2 were expressed on cell membrane and seemed to be co-localizated. In conclusion, PCDH10 variant 1 can suppress cell proliferation and invasion in HCT116, suggesting that PCDH10 variant 1 might be a putative tumor suppressor gene associated with colorectal tumorigenesis. | en |
| dc.description.provenance | Made available in DSpace on 2021-05-20T20:06:33Z (GMT). No. of bitstreams: 1 ntu-98-R96424015-1.pdf: 1520345 bytes, checksum: 49da490196e16a8093d762d5610f593f (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | Content
致謝...............................................................................................................................i 摘要...............................................................................................................................ii Abstract .........................................................................................................................iii Abbreviation ..................................................................................................................v Figure Content ............................................................................................................viii CHAPTER 1. INTRODUCTION .............................................................................1 1.2. Colorectal cancer ...................................................................................... 1 1.1.1. The colon .......................................................................................... 1 1.1.2. Risk factors ....................................................................................... 2 1.1.3. Staging .............................................................................................. 3 1.1.4. Pathways involved in colorectal tumorigenesis................................ 6 1.1.5. LOH study on chromosome 4........................................................... 9 1.2. Protocadherin 10 ..................................................................................... 11 1.2.1. Protocadherin family....................................................................... 11 1.2.2. Structure of PCDH10...................................................................... 12 1.2.3. Functional study of PCDH10 ......................................................... 12 1.2.4. PCDH10 as a novel tumor suppressor gene in various cancers...... 13 1.2.5. Previous study at our lab................................................................. 14 1.3. Objectives in the thesis ........................................................................... 16 CHAPTER 2. MATERIALS AND METHODS .....................................................17 2.1. Cell lines ................................................................................................. 17 2.2. Vector construction ................................................................................. 17 2.2.1. PCDH10 mammalian expression vector ......................................... 17 2.2.2. PCDH10-GFP mammalian expression vector ................................ 19 2.2.3. Gel purification ............................................................................... 20 2.2.4. Preparation of competent cells........................................................ 21 2.2.5. Transformation................................................................................ 21 2.2.6. Mini-preparation of plasmid DNA ................................................. 22 2.3. Cell transfection...................................................................................... 22 vii 2.4. Immunofluorescent stain......................................................................... 23 2.5. Cell proliferation assay ........................................................................... 23 2.6. Colony formation assay .......................................................................... 24 2.7. Matrigel invasion assay .......................................................................... 24 CHAPTER 3. RESULTS.........................................................................................25 3.1. Construction of PCDH10 mammalian expression vectors ..................... 25 3.2. PCDH10 expression in HEK293T.......................................................... 26 3.3. HCT116 as a model cell line................................................................... 26 3.4. PCDH10 expression in HCT116............................................................. 27 3.5. Inhibition of cell invasion ability by transient over-expression of PCDH10 variant 1 .................................................................................. 27 3.6. Suppression of cell proliferation by transient over-expression of PCDH10.................................................................................................. 27 3.7. Stable expression clones of PCDH10 in HCT116 .................................. 28 3.8. Suppression of cell proliferation and colony formation ability in one PCDH10 variant 1 stable clone .............................................................. 28 3.9. PCDH10 variant 1 and variant 2 expressed on cell membrane .............. 29 3.10. PCDH10 variant 1 and variant 2 are co-localized with homophilic interaction ............................................................................................... 30 CHAPTER4. DISCUSSION........................................................................................32 REFERENCE...............................................................................................................38 APPENDIX..................................................................................................................59 | |
| dc.language.iso | en | |
| dc.title | PCDH10 基因於大腸直腸癌之抑癌功能的鑑定 | zh_TW |
| dc.title | Identification of a putative tumor suppressor gene,
PCDH10, in colorectal cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蔡明宏,俞松良,林淑萍 | |
| dc.subject.keyword | 大腸直腸癌,抑癌基因,PCDH10, | zh_TW |
| dc.subject.keyword | colorectal cancer,tumor suppressor gene,PCDH10, | en |
| dc.relation.page | 63 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2009-08-11 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
| 顯示於系所單位: | 醫學檢驗暨生物技術學系 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf | 1.48 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
